Home > Oncology > ASCO 2019 > Lung Cancer > Overcoming the Challenges of Immunotherapy in Non–small Cell Lung Cancer

Overcoming the Challenges of Immunotherapy in Non–small Cell Lung Cancer

Presented By
Dr Sarah B. Goldberg, Dr Melissa Lynne Johnson, Dr Alexander Chi
Conference
ASCO 2019
Trial
PACIFIC, KEYNOTE-024, KEYNOTE-189

Medical writer: Jasenka Piljac Žegarac, PhD

Several experts discussed the current challenges in the use of immunotherapy in non–small cell lung cancer (NSCLC)—the most common type of lung cancer—as well as strategies to overcome them, in the Interactive Case-Based Session “Challenges in Use of Immunotherapy in NSCLC: Where the Rubber Meets the Road,” held May 31. The session was chaired by Jyoti D. Patel, MD, FASCO, of the University of Chicago Medical Centre.

“The objectives are to understand the factors that affect the risk/benefit ratio of treatment with immune checkpoint inhibitors (ICIs) in patients with advanced NSCLC and to understand what challenges this poses in patients with dysregulated immunity, chiefly those with autoimmune diseases,” Dr. Patel said.

She further noted that it is important to understand: (1) how the data hold up in patients encountered in the clinic and not just those enrolled in clinical trials; (2) which patients are to...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on